---
title: "GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295025166.md"
description: "Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T22:30:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295025166.md)
  - [en](https://longbridge.com/en/news/295025166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295025166.md)
generator: "portal-rs"
---

# GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027

Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)
- [SSNGY.US](https://longbridge.com/en/quote/SSNGY.US.md)
- [SMSN.UK](https://longbridge.com/en/quote/SMSN.UK.md)

## Related News & Research

- [GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting](https://longbridge.com/en/news/295993949.md)
- [Microsoft employees reveal how much cash they're burning on AI](https://longbridge.com/en/news/296828490.md)
- [WSHP: First half 2026 results released, highlighting platform growth and ongoing user ownership initiatives](https://longbridge.com/en/news/296829514.md)
- [HHS said to be eyeing two new FDA deputy commissioners for technology and drugs](https://longbridge.com/en/news/296945299.md)
- [ETFs RDVY, BKLC, and LSGR Get Bullish Calls from AI for Growth Potential](https://longbridge.com/en/news/296821798.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**